Releases and presentations
Stock exchange releases of BBS will be published on these pages. Releases are published in Finnish and in English.
Contact information for the media: info@bbs-artebone.fi from which you can also request additional media material
29.05.2020 BBS-Bioactive Bone Substitutes Plc: The Prospectus of Rights Issue has been published on the Company’s website today
26.05.2020 BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date
26.05.2020 BBS-Bioactive Bone Substitutes Plc: The Board of Directors of BBS-Bioactive Bone Substitutes Plc. decided on a subscription rights issue and publishes the prospectus and issue terms
20.05.2020 BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc. plans to arrange a rights issue of approximately 5.5 MEUR
09.04.2020 BBS-Bioactive Bone Substitutes Plc: Financial Statements for 2019 have been published
07.04.2020 BBS-Bioactive Bone Substitutes Plc: The patent regarding the product ARTEBONE® has been granted in the USA
07.04.2020 BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc postpones the Annual General Meeting to a later date
27.03.2020 BBS-Bioactive Bone Substitutes Plc: BBS-Bioactive Bone Substitutes Plc has received a working capital loan to secure its financing
20.03.2020 BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2019 (unaudited)
19.02.2020 BBS-Bioactive Bone Substitutes Plc: We are pleased to announce that the clinical result of ARTEBONE® is positive yielding an outcome similar to patient’s own bone graft
30.08.2018 BBS_interim_report_H1_2018_attachment
30.08.2018 BBS_osavuotiskatsaus_H1_2018_liite
17.6.2019 Spridningsemission i Sverige: Basinformationdokument Available here
Investor Meeting 3.6.2019 (Småbolagsdagen in Stockholm): the CCO of BBS-Bioactive Bone Substitutes Oyj, Paul Watkins presents the case of BBS (the presentation starts around 2:51:02). Watch the presentation
Investor Meeting 21.5.2019 (BioStock Sweden): the CCO of BBS-Bioactive Bone Substitutes Oyj, Paul Watkins presented the case of BBS
8.4.2019 BBS-Bioactive Bone Substitutes Plc: Minute of the General Annual Meeting (5.4.2019) Available here (in Finnish)
Pörssisäätiö: Company of the month: BBS-Bioactive Bone Substitutes Oyj Read more
Press Release 14.6.2018: BBS’s ARTEBONE-product as an example in the Manual of classification of medical devices Read more
4.4.2018 BBS-Bioactive Bone Substitutes Plc: Minute of the General Annual Meeting (29.3.2018) Available here
Market Bell Ceremony at Nasdaq Helsinki 28.2.2018 Watch more
Nasdaq News 28.2.2018: Nasdaq Helsinki welcomes BBS-Bioactive Bone Substitutes to Nasdaq First North Read more
28.2.2018: The shares of BBS-Bioactive Bone Substitutes Oyj are listed on the First North Finland ja First North Sweden marketplaces – The trading has started.
See the picture on higher resolution
See the picture on higher resolution
Manager’s Transactions 21.2.2018: Read more
Company’s announcement 20.2.2018: The initial public offering of BBS-Bioactive Bone Substitutes Plc ended. Listing at the Nasdaq First North Finland and Sweden marketplaces have been applied – Trading begins about 28.02.2018. Read more
Company’s announcement 16.2.2018: BBS-Bioactive Bone Substitutes Plc applies for its shares to be listed on the Nasdaq First North Finland and the Nasdaq First North Sweden marketplaces. Read more
Press release 15.2.2018: År av smärtan försvann helt – Den legendariska finska Formel 1 kommentatorn Erkki Mustakaris vrist behandlades med bensubstitut baserad på renben och utvecklat av BBS-Bioactive Bone Substitutes Oyj. Read more
Interviews 5.2.2018 (Nordnet Sweden): Nordnet Sweden interviews the CEO of BBS-Bioactive Bone Substitutes Oyj, prof. Pekka Jalovaara and member of the Advisory Board, Kirk Andriano. Watch
Advisor’s interview 31.1.2018 (Nasdaq): BBS-Bioactive Bone Substitutes Oyn announced its intention to launch an IPO. Watch
Press release 31.1.2018: BBS-Bioactive Bone Substitutes Oyj announces its intention to launch an initial public offering and plans to apply for its shares to be listed on the Nasdaq First North Finland and Sweden marketplaces. Read more